Jennifer Marks, Thoracic Oncologist at Dana-Farber Cancer Institute, shared a post on X:
“ABBV-706 [SEZ6 – ADC] in second-line small cell lung cancer showed objective response rate of 82% (14/17), with activity even in platinum-refractory/resistant disease and clinical benefit rate exceeding 94%.
Early days, but an agent to continue to watch in relapsed SCLC.”
Other articles featuring Dr. Marks on OncoDaily.
